Challenges and Opportunities While Developing a Group A Meningococcal Conjugate Vaccine Within a Product Development Partnership: A Manufacturer's Perspective From the Serum Institute of India

Development and Use of a Serum Bactericidal Assay Using Pooled Human Complement To Assess Responses to a Meningococcal Group A Conjugate Vaccine in African Toddlers

(2014) Margaret C. Bash et al.   Clinical and Vaccine Immunology

Vaccines against poverty

(2014) C. A. MacLennan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Impact of the Serogroup A Meningococcal Conjugate Vaccine, MenAfriVac, on Carriage and Herd Immunity

(2012) Paul A. Kristiansen, Fabien Diomandé, Absatou Ky Ba, Idrissa Sanou, Abdoul–Salam Ouédraogo, Rasmata Ouédraogo, Lassana Sangaré, Denis Kandolo, Flavien Aké, Inger Marie Saga, Thomas A. Clark, Lara Misegades, Stacey W. Martin, Jennifer Dolan Thomas, Sylvestre R. Tiendrebeogo, Musa Hassan-King, Mamoudou H. Djingarey, Nancy E. Messonnier, Marie-Pierre Préziosi, F. Marc LaForce, Dominique A. Caugant   CLINICAL INFECTIOUS DISEASES

Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data

(2012) Ryan T Novak et al.   LANCET INFECTIOUS DISEASES

Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2–10 years: A Phase II/III double-blind randomized controlled trial

(2012) Siddhivinayak Hirve et al.   VACCINE

Eliminating Epidemic Group A Meningococcal Meningitis In Africa Through A New Vaccine

(2011) F. Marc LaForce et al.   HEALTH AFFAIRS

Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in Africans

(2011) Samba O. Sow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa

(2008) Che-Hung Lee et al.   VACCINE